MDMA-Assisted Therapy for PTSD: Does It Work? What the Trials Showed, and Why the FDA Rejected It

Post-traumatic stress disorder (PTSD) is one of those mental health conditions where standard treatment — trauma-focused memory-processing therapy and SSRIs — helps many patients, but symptoms persist for years in a significant portion, and dropout rates are high. There hadn't been a new, approved drug for PTSD in over two decades, which partly explains why MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy generated so much interest as its clinical trial results began to publish.

In August 2024, this story took an unexpected turn: the US Food and Drug Administration (FDA) refused to approve the drug, despite two positive phase 3 trials. This article lays out both sides of that story honestly — the real, measurable clinical results behind the enthusiasm, and the specific, documented concerns that led to the registration refusal. Neither side cancels out the other; both are needed to understand where this therapy actually stands at the start of 2026.

The MAPP1 result was a significant signal — the first fully randomized phase 3 trial of MDMA-assisted therapy, published in the prestigious journal Nature Medicine, showing statistically significant, clinically meaningful improvement. For the psychedelic research community, it was a breakthrough moment, comparable to the first positive esketamine trials for depression.

Despite two positive phase 3 trials, on August 9, 2024, the FDA issued a complete response letter (CRL) — a formal refusal — in response to Lykos Therapeutics's (formerly part of MAPS, the organization that has funded MDMA research for decades) application to approve midomafetamine (the active substance name for MDMA) for PTSD therapy. The agency stated that the submitted data did not allow it to conclude the drug was safe and effective for the proposed indication, and requested an additional phase 3 trial.

The FDA's decision wasn't a complete surprise to those following the earlier course of the registration process. In June 2024, two months earlier, an independent FDA advisory panel (the Psychopharmacologic Drugs Advisory Committee) voted against approval — 9 votes against versus 2 in favor on efficacy, and 10 against versus 1 in favor on the overall risk-benefit balance. This panel's recommendations, while formally non-binding, usually correlate strongly with the FDA's final decision.

This limitation isn't unique to MDMA trials — the same problem affects, in practice, all trials of psychedelic substances, including those discussed in our entry on psilocybin therapy for depression. The difference with MDMA is that the FDA and its advisory panel considered this problem serious enough, combined with questions about trial conduct reliability, to block registration, despite formally positive statistical results in both phase 3 trials.

Lykos Therapeutics called the FDA's decision deeply disappointing and argued that a significant portion of the agency's concerns could be addressed through post-marketing monitoring requirements or by referencing existing scientific literature, without needing to run an entirely new, multi-year phase 3 trial from scratch. The company also criticized the advisory panel process itself, arguing that the discussion went beyond the substantive content of the documentation submitted for review, and that the number of psychedelics experts on the panel was limited.

Regardless of how one assesses this criticism, the practical outcome is clear: the FDA requested a new phase 3 trial, which in practice means a multi-year delay in any eventual US registration. As of this article's writing (2026), MDMA-assisted therapy remains an unregistered drug in the US, the European Union and Poland — available only within ongoing clinical trials, nowhere as a standard treatment option.

It's also worth noting that the FDA's decision concerns a specific American registration process and a specific sponsor (Lykos Therapeutics) — it doesn't definitively close the door on MDMA-assisted therapy as such. Other research teams may in the future present new, more rigorously designed trials, and regulators in other countries (e.g. Australia, where MDMA-assisted therapy has been available in a limited capacity since 2023 under a special access program) may make separate regulatory decisions independent of the US FDA's position.

The story of MDMA-assisted therapy for PTSD is a good example of how promising clinical trial results and serious regulatory doubts can coexist without canceling each other out. Two phase 3 trials showed a real, reproducible clinical signal — but methodological limitations inherently tied to trials of psychedelic substances, combined with specific questions about the reliability of some trials' conduct, proved sufficient to block registration in the US in 2024.